Todd Asset Management LLC Makes New $216,000 Investment in Eli Lilly and Company (NYSE:LLY)

Todd Asset Management LLC acquired a new position in shares of Eli Lilly and Company (NYSE:LLY) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 371 shares of the company’s stock, valued at approximately $216,000.

Several other institutional investors also recently bought and sold shares of LLY. Simon Quick Advisors LLC lifted its position in Eli Lilly and Company by 10.5% during the 4th quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock worth $1,706,000 after acquiring an additional 278 shares during the period. Clear Harbor Asset Management LLC acquired a new stake in Eli Lilly and Company in the 4th quarter worth about $363,000. Terril Brothers Inc. increased its position in Eli Lilly and Company by 113.2% during the fourth quarter. Terril Brothers Inc. now owns 808 shares of the company’s stock worth $471,000 after purchasing an additional 429 shares during the last quarter. Hartline Investment Corp raised its position in shares of Eli Lilly and Company by 1.1% in the 4th quarter. Hartline Investment Corp now owns 21,934 shares of the company’s stock worth $12,786,000 after buying an additional 248 shares during the period. Finally, Commonwealth Equity Services LLC increased its position in Eli Lilly and Company by 5.2% during the 4th quarter. Commonwealth Equity Services LLC now owns 354,565 shares of the company’s stock worth $206,683,000 after purchasing an additional 17,461 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

LLY has been the topic of a number of recent research reports. Cantor Fitzgerald reissued an “overweight” rating and set a $885.00 target price (up from $815.00) on shares of Eli Lilly and Company in a research report on Tuesday, April 30th. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. The Goldman Sachs Group lifted their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research note on Thursday, April 11th. Truist Financial increased their price target on Eli Lilly and Company from $850.00 to $892.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, JPMorgan Chase & Co. raised their target price on Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a research note on Wednesday. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $757.95.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock traded down $20.94 during midday trading on Friday, reaching $734.97. The company’s stock had a trading volume of 4,595,138 shares, compared to its average volume of 2,629,045. The stock has a market cap of $698.52 billion, a PE ratio of 108.24, a price-to-earnings-growth ratio of 1.46 and a beta of 0.37. The company has a current ratio of 1.35, a quick ratio of 0.73 and a debt-to-equity ratio of 1.90. The business has a 50-day moving average price of $761.06 and a 200-day moving average price of $671.38. Eli Lilly and Company has a 52 week low of $419.80 and a 52 week high of $800.78.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Tuesday, April 30th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The firm had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. During the same period in the previous year, the business earned $1.62 EPS. The business’s quarterly revenue was up 26.0% compared to the same quarter last year. On average, sell-side analysts predict that Eli Lilly and Company will post 13.82 EPS for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.